Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

GW 501516

HY-10838

(GW 1516; GSK-516; GW-501516)

GW 501516

GW 501516 Chemical Structure

GW501516(GSK-516; GW1516) is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $78 In-stock
50 mg $190 In-stock
100 mg $260 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €54 In-stock
5 mg €49 In-stock
10 mg €76 In-stock
50 mg €186 In-stock
100 mg €255 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: GW 501516
Cat. No.: HY-10838

GW 501516 Data Sheet

  • View current batch:

    Purity: 98.91%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of GW 501516

GW501516(GSK-516; GW1516) is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.
IC50 Value: 1 nM(EC50)
Target: PPARβ/δ
in vitro: GW501516 is demonstrated to be 1000-fold more selective in comparison to existing subtypes. GW501516 increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux In macrophages, fibroblasts, and intestinal cells. GW501516 can regulate expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Additionally, GW501516 is shown to block insulin resistance and fatty acid-induced nuclear factor-κB activation. GW 501516 reduces the IFNγ-induced up-regulation of TNFα and inducible NO synthase, and showed anti-inflammatory activity.
in vivo: GW501516 dramatically increases serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin when dosed to insulin-resistant middle-aged obese rhesus monkeys. GW501516 induces fatty acid β-oxidation in L6 myotubes and in mouse skeletal muscles. GW501516 treatment to mice fed a high-fat diet ameliorates diet-induced obesity as well as insulin resistance. GW501516 treatment also dramatically improves diabetes, as demonstrated by the decrease in plasma glucose and blood insulin levels in genetically obese ob/ob mice.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 453.5 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C21H18F3NO3S2
CAS No 317318-70-0
Solvent & Solubility

DMSO:50 mg/ml; DMF:25 mg/ml;methanol: 50 mg/ml;

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.2051 mL 11.0254 mL 22.0507 mL
5 mM 0.4410 mL 2.2051 mL 4.4101 mL
10 mM 0.2205 mL 1.1025 mL 2.2051 mL

References on GW 501516

Inhibitor Kit

Related PPAR Products

  • Aleglitazar

    Aleglitazar(R1439; RO-0728804) is a new dual PPAR-(alpha)/(gamma) agonist with IC50 of 2.8 nM/4.6 nM.

  • Balaglitazone

    Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-(gamma).

  • Bezafibrate

    Bezafibrate(BM15075) is the first clinically tested dual and pan-PPAR co-agonism.

  • BMS-687453

    BMS-687453 is a potent and selective PPAR(alpha) agonist, with an EC50 of 10 nM for human PPAR(alpha) and 410-fold selectivity vs human PPAR(gamma) in PPAR-GAL4 transactivation assays.

  • CDDO-Im

    CDDO-Im(RTA-403) is a novel synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo; PPAR(gamma) agonist.

  • Clofibrate

    Clofibrate (Atromid-S), a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

  • DG172 dihydrochloride

    DG172 dihydrochloride is a novel PPAR(beta)/(delta)-selective ligand showing high binding affinity (IC50 = 27 nM) and potent inverse agonistic properties.

  • Elafibranor

    Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor(PPAR)-(alpha) and -(delta), induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

  • Fenofibrate

    Fenofibrate is PPAR(alpha) agonist with EC50 of 18 (mu)M and 30 (mu)M for mouse and human PPAR(alpha), respectively.

  • FH535

    FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.

MORE